Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1467)
All Articles published online
|
Publishing Process of This Article
|
Oct 28, 2025 (publication date) through May 1, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Anis MA, Shahid Y, Majeed AA, Abid S. Microbiome and gut-liver interactions: From mechanisms to therapies. World J Gastroenterol 2025; 31(40): 111409 [PMID: 41180995 DOI: 10.3748/wjg.v31.i40.111409] |
|
|
|
| All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. | |
| For: | Anis MA, Shahid Y, Majeed AA, Abid S. Microbiome and gut-liver interactions: From mechanisms to therapies. World J Gastroenterol 2025; 31(40): 111409 [PMID: 41180995 DOI: 10.3748/wjg.v31.i40.111409] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v31/i40/111409.htm |
| Number | Citing Articles |
| 1 |
Jiwen Cheng. The Microbiome‐Gut‐Liver Axis Drives Post‐Kasai Fibrosis in Biliary Atresia: From Mechanism to Precision Intervention. Hepatology Research 2026; doi: 10.1111/hepr.70184
|
| 2 |
Sheng-Sheng Liu, Lei Ye, Xiao-Xue Li, Qing-Qing Dai, Yi Gao, Guang-Hou Chen, Yong-Sheng Fang, Hong-Chuan Zhao, Wei-Dong Du. Intratumoral microbiome evaluated progression and outcome of patients with HBV-associated hepatocellular carcinoma. Discover Oncology 2026; 17(1) doi: 10.1007/s12672-026-04654-5
|
| 3 |
Amedeo Lonardo, Ralf Weiskirchen. Drug treatment of MASH from none to (too) many options?. Exploration of Medicine 2025; 6 doi: 10.37349/emed.2025.1001378
|
| 4 |
Xiang Gao, Song Dai, Jiahao Li, Tao Wang, Xulong Sun, Pengzhou Li. Odevixibat ameliorates high-fat diet-induced MASLD in mice by targeting the gut microbiota-metabolite axis and enhancing gut-liver crosstalk. Journal of Physiology and Biochemistry 2026; 82(1) doi: 10.1007/s13105-026-01165-3
|